HeartFlow and Glenview Capital-backed Longview Acquisition II terminated a $2.4bn deal.

HeartFlow, a precision heart care firm, and Glenview Capital-backed Longview Acquisition II, a SPAC, terminated a $2.4bn deal. “We believe that our non-invasive, artificial intelligence-enabled, cloud-based enterprise software solution can transform cardiovascular care with risk assessment, diagnosis planning and treatment management. Importantly, we have brought together a talented group of individuals with deep expertise in technology, cardiovascular medicine, and the business of healthcare and a deep commitment to patients to deliver on this vision,” John H. Stevens, HeartFlow MD, President, CEO and Co-Founder.